Developing new methods for creating complex organic molecules
Official title: Novel Transition Metal Catalysis for Chemical Synthesis
Funded at University of Texas Dallas · NIH-11011701 · Data updated 2026-11-12
This study is exploring a new way to make important changes to organic molecules that are used in medicines, using light to make the process easier and safer, which could help create drugs more efficiently and affordably.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | April 22, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $460,413 |
| NIH project number | 1R35GM156632-01 |
| Project ID | NIH-11011701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals involved in pharmaceutical development or those requiring novel drug formulations.
✕Less likely to help
Patients who are not involved in drug development or do not require new pharmaceutical interventions may not benefit from this research.
What this research studies
This research focuses on creating a new platform for the selective functionalization of organic molecules, which are essential for drug development. By utilizing non-functionalized substrates, the research aims to simplify the process of modifying complex biologically important molecules. The approach involves a novel catalytic methodology that uses visible light to enable controlled reactions without the need for harsh conditions or external oxidants. This could lead to more efficient and cost-effective methods for synthesizing pharmaceuticals.
Why it matters
Potential benefit: If successful, this research could significantly enhance the efficiency of drug discovery and development processes.
How similar studies have gone: While the approach is innovative, similar methodologies in catalysis have shown promise in other contexts, suggesting potential for success.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Gevorgyan, Vladimir — University of Texas Dallas
- Study coordinator: Gevorgyan, Vladimir
Related research
Other NIH-funded projects on the same topics.
-
Profilin as a Target to Normalize Tumor Vessels in Kidney Cancer
A new approach aims to curb blood vessel growth in a common kidney cancer by targeting a protein called Profilin 1 to improve how blood vessels form in tumors.
-
Ultrafast debinding for chairside 3D-printed zirconia dental restorations
A new ultrafast debinding method aims to dramatically shorten how quickly chairside 3D-printed zirconia dental crowns can be made.
-
Adolescents learning about themselves through friends and how it links to mood
A study with teens will test how feedback from close friends and strangers shapes their self-views and mood, using brain and behavior measurements.
-
Bilingual children with developmental language disorder: how two languages shape brain development
A study with bilingual kids who have developmental language disorder to see how knowing two languages affects their brain and language skills.
-
BET inhibitors as a potential therapy for solitary fibrous tumor (SFT)
Aimed at adults with solitary fibrous tumor, this grant explores BET inhibitors to block tumor-driving gene activity.
-
Estrogen, puberty, and early signs of psychosis in teens
This grant looks at how rising estrogen during puberty in girls may influence early brain changes and psychotic-like experiences as kids become teens.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.